Zhejing Meihua Dingchang Pharmaceutical Co. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zhejing Meihua Dingchang Pharmaceutical Co. Ltd. - overview
Established
2011
Location
Shaoxing, Zhejiang, China
Primary Industry
Biotechnology
About
Established in 2011 and based in Shaoxing, China, Zhejing Meihua Dingchang Pharmaceutical Co. Ltd. is a biomedical company that focuses on product development of new drugs and generic new drugs. The chairman and general manager Dr.
Chuanyue Wang graduated from the University of Ghent, Belgium with a PhD. She worked in Wyeth Pharmaceuticals Global Analysis and Development Center and Teva Pharmaceuticals in drug research. In July 2021, the company raised series B funding from new investor. The company provides generic new drug formulations research and development, cGMP (current good manufacture practices) quality standard control, innovative drug development, analytical testing, and project approval to FDA services for biopharmaceutical industry.
The company's main self-developed products include oral controlled-release, bio-peptide and essential oil tablets and so on. The company plans to use the fund of series B funding to promote the construction of GMP (good manufacture practices) production line for innovative microsphere long-acting injections.
Current Investors
Xingyuan Asset Management, Jinju Capital, Oriental Fortune Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.mhdcpharma.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.